Biotechnology
/
Eastern Norway

Synthetica AS
CUSTOM SYNTHESIS & CONTRACT RESEARCH

Africa
Asia
Denmark
Europe
North America
Oceania
South America
South Asia
Sweden
West Asia
  • Finance
    Total revenues: 24.662
    Operating profit: -1.263
    Operating profit before tax: -1.477
    Total assets: 6.939
    Total equity: 356
    Currency: NOK (all numbers in thousands)
  • Management
    Board Chairman:
    Egil Greve

    Board Members:
    Inger Reidun F Aukrust
    Kai Schröder

    General Manager:
    Inger Reidun F Aukrust

    Subsidiary companies:
    Largest shareholders:
    N/A
    Biotechnology, Health Care, Research and experimental development services,